Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.33 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.33 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.33 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.33 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.33 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15827486 | 0.90 | KMT2A (0.39) | BTKGAAMEN1MAPK1KMT2A | |
| SCHEMBL27963434 | 0.84 | BTK (0.38) | BTKGAAMEN1MAPK1KMT2A | |
| SCHEMBL16654374 | 0.84 | BTK (0.38) | BTKGAAMEN1MAPK1KMT2A | |
| SCHEMBL3052729 | 0.81 | BTK (0.46) | BTKGAAMEN1MAPK1KMT2A | |
| SCHEMBL17007379 | 0.81 | BTK (0.46) | BTKGAAMEN1MAPK1KMT2A | |
| SCHEMBL27963435 | 0.81 | BTK (0.38) | BTKGAAMEN1MAPK1KMT2A | |
| SCHEMBL3378203 | 0.80 | BTK (0.35) | BTKGAAMEN1MAPK1KMT2A | |
| SCHEMBL17007311 | 0.80 | BTK (0.35) | BTKGAAMEN1MAPK1KMT2A | |
| SCHEMBL28834730 | 0.79 | BTK (0.35) | BTKGAAMEN1MAPK1KMT2A | |
| SCHEMBL28055198 | 0.77 | HSD11B1 (0.35) | BTKGAAMEN1MAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10011588-B2 | 1,2-substituted cyclopentanes as orexin receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-07-03 | — | — | US | disclosed |
| US-20170066744-A1 | 1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-09 | — | — | US | disclosed |
| US-9493432-B2 | Cyclopentylbenzamide derivatives and their use for the treatment of psychotic and cognitive disorders | TAKEDA PHARMACEUTICALS COMPANY LIMITED (JP) | 2016-11-15 | — | — | US | disclosed |
| US-20160222030-A1 | Cyclopentylbenzamide Derivatives and their Use for the Treatment of Psychotic and Cognitive Disorders | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-08-04 | — | — | US | disclosed |
| US-9156829-B2 | Cycloalkyl and heterocycloalkyl compounds as orexin receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-13 | — | — | US | disclosed |
| US-20150232460-A1 | NOVEL COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160222030-A1 | Cyclopentylbenzamide Derivatives and their Use for the Treatment of Psychotic and Cognitive Disorders | CNR1, GABRR1, GRIN2A | BTK 2192/4885GAA 1473/4885MEN1 4694/4885 |
| US-10011588-B2 | 1,2-substituted cyclopentanes as orexin receptor antagonists | HCRTR1, HCRTR2, NPY1R | BTK 2501/4885GAA 2704/4885MEN1 1052/4885 |
| US-20170066744-A1 | 1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR1, HCRTR2, NPY1R | BTK 2501/4885GAA 2704/4885MEN1 1052/4885 |
| US-20150232460-A1 | NOVEL COMPOUNDS | CNKSR1, RDX, RB1 | BTK 772/4885GAA 1114/4885MEN1 2376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.